Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia

被引:18
作者
Avi, Radko [1 ]
Huik, Kristi [1 ]
Sadam, Maarja [1 ]
Karki, Tonis [1 ]
Krispin, Tonu [1 ]
Ainsalu, Kuelliki [2 ]
Paap, Piret [3 ]
Schmidt, Jelena [4 ]
Nikitina, Natalia [4 ]
Lutsar, Irja [1 ]
机构
[1] Univ Tartu, Fac Med, Dept Microbiol, EE-50111 Tartu, Estonia
[2] Tartu Univ Hosp, Dept Infect Dis, Tartu, Estonia
[3] Hosp Tartu Prison, Tartu, Estonia
[4] Ida Viru Cent Hosp, Kohtla Jarve, Estonia
关键词
natural polymorphism; drug resistance mutation; protease; revertase; FORMER SOVIET-UNION; HIV TYPE-1; SUBTYPE-B; MUTATIONS; PROTEASE; RECOMBINANT; STRAINS; EPIDEMIOLOGY; DIVERSITY; THERAPY;
D O I
10.1002/jmv.21482
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
All non-B HIV-1 subtypes and circulating recombinant forms (CRFs) are characterized by several polymorphisms in protease (PR) region. In addition, in recent years the increasing use of antiretroviral treatment (ART) has rapidly raised the spread of transmitted drug resistance. We aimed to determine the presence of naturally Occurring polymorphisms and transmitted drug resistance mutations (DRMs) in ART naive HIV-1-positive subjects in Estonia. A total of 115 drug-naive HIV-1-infected subjects (mean age 27 years; 70% male; 65% infected via intravenous drug use and 34% by heterosexual contact) were enrolled. Viral genomic RNA from plasma was directly sequenced in PR, revertase (RT), and envelope (env) regions. Phylogenetic analysis of RT and env regions revealed that 89% and 3% of sequenced viruses belonged to CRF06_cpx and subtype All, respectively, and 6% were described as unique recombinants (signed A1-06) between CRF06_cpx and subtype All viruses. No primary DRMs were found in PR or RT regions indicating the absence of transmitted drug resistance. The most common polymorphisms in the PR region were K14R, M36I, H69K, and L89M seen in 96%, 100%, 99%, and 100%, respectively. The clinical relevance of these polymorphisms in terms of success of ART has to be monitored in future clinical studies. J. Med. Virol. 81:953-958, 2009. (c) 2009 Wiley-Liss, Inc.
引用
收藏
页码:953 / 958
页数:6
相关论文
共 28 条
[1]  
Adojaan M, 2005, JAIDS-J ACQ IMM DEF, V39, P598
[2]   Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (Subtype E) infection differ from subtype B infection [J].
Ariyoshi, K ;
Matsuda, M ;
Miura, H ;
Tateishi, S ;
Yamada, T ;
Sugiura, W .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (03) :336-342
[3]   A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union:: Identification of subtype A, subtype B, and novel gagA/envB recombinants [J].
Bobkov, A ;
Kazennova, E ;
Selimova, L ;
Bobkova, M ;
Khanina, T ;
Ladnaya, N ;
Kravchenko, A ;
Pokrovsky, V ;
Cheingsong-Popov, R ;
Weber, J .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (08) :669-676
[4]   Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom [J].
Cane, PA ;
de Ruiter, A ;
Rice, P ;
Wiselka, M ;
Fox, R ;
Pillay, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) :2652-2654
[5]   HIV-1 subtypes: epidemiology and significance fov HIV management [J].
Geretti, AM .
CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (01) :1-7
[6]   Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases [J].
Gonzalez, LMF ;
Brindeiro, RM ;
Aguiar, RS ;
Pereira, HS ;
Abreu, CM ;
Soares, MA ;
Tanuri, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3552-3555
[7]   Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays [J].
Gonzalez, R ;
Masquelier, B ;
Fleury, H ;
Lacroix, B ;
Troesch, A ;
Vernet, G ;
Telles, JN .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (07) :2907-2912
[8]   Mutation D30N is not preferentially selected by human immunodeficiency virus type I subtype C in the development of resistance to nelfinavir [J].
Grossman, Z ;
Paxinos, EE ;
Averbuch, D ;
Maayan, S ;
Parkin, NT ;
Engelhard, D ;
Lorber, M ;
Istomin, V ;
Shaked, Y ;
Mendelson, E ;
Ram, D ;
Petropoulos, CJ ;
Schapiro, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2159-2165
[9]   Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration [J].
Kantor, R ;
Katzenstein, DA ;
Efron, B ;
Carvalho, AP ;
Wynhoven, B ;
Cane, P ;
Clarke, J ;
Sirivichayakul, S ;
Soares, MA ;
Snoeck, J ;
Pillay, C ;
Rudich, H ;
Rodrigues, R ;
Holguin, A ;
Ariyoshi, K ;
Bouzas, MB ;
Cahn, P ;
Sugiura, W ;
Soriano, V ;
Brigido, LF ;
Grossman, Z ;
Morris, L ;
Vandamme, AM ;
Tanuri, A ;
Phanuphak, P ;
Weber, JN ;
Pillay, D ;
Harrigan, PR ;
Camacho, R ;
Schapiro, JM ;
Shafer, RW .
PLOS MEDICINE, 2005, 2 (04) :325-337
[10]   Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France [J].
Lawrence, Philip ;
Lutz, Marie-France ;
Saoudin, Henia ;
Fresard, Anne ;
Cazorla, Celine ;
Fascia, Pascal ;
Pillet, Sylvie ;
Pozzetto, Bruno ;
Lucht, Frederic ;
Bourlet, Thomas .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 42 (04) :396-404